Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pretransplant History, Melanoma Outcomes Examined

Melanoma Res; ePub 2018 Jun 26; Puza, Barbas, et al

In well-selected patients with a history of early-stage melanoma and an appropriate time interval between melanoma treatment and transplant, post-transplant outcomes are favorable. This according to a recent study that investigated how a pretransplant history of melanoma impacts patient survival and melanoma recurrence. Duke University’s retrospective database was used to identify 4,552 patients who underwent a solid organ transplant at the university from January 1, 2001, to December 31, 2016. Data with regard to the transplant, melanoma characteristics, rejection episodes, and survival were recorded. Researchers found:

  • Of total patients who underwent a solid organ transplant, 12 (0.3%) had a history of melanoma before transplant (6 with melanoma in situ and 6 with stage I disease).
  • The median time between melanoma diagnosis and transplant was 4.13 years (range: 1.1–13.3 years).
  • The study cohort consisted of 4 liver transplants, 4 lung transplants, 1 kidney transplant, 1 heart transplant, 1 small bowel transplant, and 1 multivisceral transplant.
  • At the median follow-up time of 2.8 years, 10 (83.3%) patients were alive.
  • In nonmelanoma cohorts, the 3-year survival is 70% for thoracic transplants, 78% for liver transplants, and 88% for kidney transplants.

Citation:

Puza CJ, Barbas AS, Mosca PJ. Outcomes of patients with a pretransplant history of early-stage melanoma. [Published online ahead of print June 25, 2018]. Melanoma Res. doi:10.1097/CMR.0000000000000471.